Skip to main content

Neuronetics, Inc. (STIM) Stock Forecast

Data as of May 3, 2026

Healthcare · Current price $1.97 (+1.55%)

Consensus Target
$8.00
Upside
+306.1%
Analysts
1
Rating
Buy(2.00)

Price Target Range

Low $8.00High $8.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Nov 8, 2022Adam MaederPiper Sandler$8.00+306.1%

STIM vs Sector & Market

MetricSTIMHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count1818
Target Upside+306.1%+1149.9%+14.9%
P/E Ratio-2.896.8731.19

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$160M$162M$165M2
2027-12-31$179M$182M$184M2
2028-12-31$210M$213M$216M1
2029-12-31$234M$237M$240M1
2030-12-31$259M$263M$266M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.48$-0.48$-0.472
2027-12-31$-0.32$-0.32$-0.312
2028-12-31$-0.18$-0.18$-0.181
2029-12-31$-0.08$-0.08$-0.081
2030-12-31$-0.05$-0.05$-0.051

Frequently Asked Questions

What is the analyst consensus for STIM?

The consensus among 1 analysts covering Neuronetics, Inc. (STIM) is Buy with an average price target of $8.00.

What is the highest price target for STIM?

The highest price target for STIM is $8.00, set by Adam Maeder at Piper Sandler on 2022-11-08.

What is the lowest price target for STIM?

The lowest price target for STIM is $8.00, set by Adam Maeder at Piper Sandler on 2022-11-08.

How many analysts cover STIM?

1 analysts have issued ratings for Neuronetics, Inc. in the past 12 months.

Is STIM a buy or sell right now?

Based on 1 analyst ratings, STIM has a consensus rating of Buy (2.00/5) with a +306.1% upside to the consensus target of $8.00.

What are the earnings estimates for STIM?

Analysts estimate STIM will report EPS of $-0.48 for the period ending 2026-12-31, with revenue estimated at $162M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.